Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant

Summary

This is a Phase II non-randomized, open, uncontrolled and bi-centric study of hormonal induction by exemestane (Aromasin) + tamoxifen to evaluate the effectiveness of exemestane (Aromasin) with tamoxifen on the rate of clinical response menopausal in patients with tumors of locally advanced breast. Hormone therapy will be administered at a dose of 25mg/day for exemestane and 20 mg / day for 4 months for tamoxifen.

Timeline

Start

2002-01

Primary completion

2006-06

Completion

2006-06

Drugs

Indications